PD-1 Combined with VEGF/VEGFR2 Inhibitors for the Re-Treatment of Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal carcinoma has a good prognosis with intensity-modulated radiotherapy (IMRT) but recurrence occurs in 8-10% of patients, mostly in the form of distant metastases. Current systemic treatments for relapsed/metastatic (R/M) IP: 2038 10920 On: Tue 27 Jun 2023 11:27:35 nasopharyngeal carcinoma are limited, resulting in poor overall survival rates. Immune checkpoint inhibitors have shown Copyright: American Scientific Publshers some activity, but their small sample size and lackofDeliverdoverallbysurIngenvivaladata limit their effectiveness. This study reports a patient with R/M nasopharyngeal carcinoma who had a durable response to salvage therapy with camrelizumab plus anlotinib, with no serious side effects and high quality of life. The combination of immune checkpoint inhibitors and anti -vascular monoclonal antibodies may have a mechanism for enhancing the antitumor response. VEGF/VEGFR2 inhibitors combined with PD-1 inhibitors are being clinically explored as a potential new treatment option for R/M nasopharyngeal carcinoma. These findings offer hope for the development of effective, tumor-specific treatments for patients with R/M nasopharyngeal carcinoma.